Nasal Administration
A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit which is operable to deliver the powdered substance through the nosepiece.
1 - 92 . (canceled)
93 . A delivery device for delivering a powdered substance to the posterior region of a nasal cavity of a subject, the delivery device comprising:
a nosepiece for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject; and
a substance supply unit which is operable to deliver the powdered substance through the nosepiece, wherein the substance supply unit contains a powdered sumatriptan substance comprising a particle size distribution in which at least 10% of the particles are less than about 20 μm, at least 50% of the particles are less than about 50 μm, at least 50% of the particles are greater than about 30 μm, and at least 90% of the particles are less than about 150 μm, and wherein the powdered substance.
94 . The delivery device of claim 93 , wherein the powdered sumatriptan substance comprises a sumatriptan base or sumatriptan succinate.
95 . The delivery device of claim 93 , wherein the powdered sumatriptan substance contains only sumatriptan succinate and no introduced excipients or adjuvants.
96 . The delivery device of claim 93 , wherein the substance supply unit contains a 10mg dose of the powdered sumatriptan substance.
97 . The delivery device of claim 93 , wherein the powdered sumatriptan substance has a particle size distribution in which at least 10% of the particles are less than about 10 μm and at least 90% of the particles are less than about 90 μm.
98 . A substance containing unit containing a powdered sumatriptan substance comprising a particle size distribution in which at least 10% of the particles are less than about 20 μm, at least 50% of the particles are less than about 50 μm, at least 50% of the particles are greater than about 30 μm, and at least 90% of the particles are less than about 150 μm, and wherein the powdered substance has an untapped bulk density of between about 0.3 g/ml and about 0.5 g/ml.
99 . The substance containing unit of claim 98 , wherein the powdered sumatriptan substance comprises a sumatriptan base or sumatriptan succinate.
100 . The substance containing unit of claim 98 , wherein the powdered sumatriptan substance contains only sumatriptan succinate and no introduced excipients or adjuvants.
101 . The substance containing unit of claim 98 , wherein the substance containing unit comprises a capsule.
102 . The substance containing unit of claim 98 , wherein the substance containing unit contains a 10 mg dose of the powdered sumatriptan substance.
103 . The substance containing unit of claim 98 , wherein the powdered sumatriptan substance has a particle size distribution in which at least 10% of the particles are less than about 10 μm and at least 90% of the particles are less than about 90 μm. comprises carboxymethylcellulose.